Abstract

Aim. Despite scientific and clinical success, glioblastoma remains the most aggressive tumor of the brain with extremely low prognostic potential for the patient. Biomarkers determining prognosis, and hence a treatment strategy, remains an actual problem at the moment. miRNAs can be considered as markers of glioblastoma. World’s long-term study confirm the legitimacy of miRNAs usage as reliable markers for the tumors diagnosis and prognosis, in particular brain tumors. The purpose of our study was miRNAs targeting, the change in expression of which in gliomas can be reliably associated with malignancy degree and tumor progression. Methods. To achieve the purpose of the investigation there were used such methods as bioinformatics search of the miRNAs for 3’-UTR genes associated with gliomas development, RNA isolation and miRNA-specific synthesis of cDNAs. The expression levels of miRNAs were determined by the real-time quantitative PCR (qPCR). The relative expression levels of targeted miRNAs were evaluated by comparing their content in tumor and adjacent tissues, conditionally healthy brain tissues of the same patients. Results. The analysis of qPCR results showed a decreased concentration of miR-30a-5p and miR-200c-3p in brain tumors relative to adjacent normal tissue in average of the 5 and 5.8 times, respectively (p <0.0001). Area under the ROC curve analysis of miR-30a-5p was AUC = 0.88528, for miR-200c-3p - AUC = 0.808. Conclusions. As an additional diagnostic and prognostic marker of glibalastoma signature determination, the expression level of hsa-miR-30a-3p and hsa-miR-200c-3p showed a good diagnostic potential (AUC = 7-9).
 Keywords: glioblastoma, microRNA, hsa-miR-30a-5p, hsa-miR-200c-3p.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.